Latest ALV003 Stories
Alvine Pharmaceuticals Reports Positive Results With ALV003 in Phase 1 Trial of Therapy in Development for Celiac Disease
Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease.
Word of the Day
- A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.